Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. R1 RCM Inc.
  6. News
  7. Summary
    RCM   US7493971052

R1 RCM INC.

(RCM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

R1 RCM Announces Pricing of Secondary Offering of 15,000,000 Shares by Selling Stockholders

05/26/2021 | 09:22pm EDT

CHICAGO, May 26, 2021 (GLOBE NEWSWIRE) -- R1 RCM Inc. (“R1 RCM” or the “Company”) (NASDAQ: RCM) announced that it has priced the underwritten offering of 15,000,000 shares of its common stock by selling stockholders at a price to the public of $22.50 per share. The selling stockholders are TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners L.P., and Joseph Flanagan, the President and Chief Executive Officer of the Company. The underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from TCP-ASC. The offering is expected to close on June 1, 2021, subject to the satisfaction or waiver of customary closing conditions. R1 RCM is not selling any shares in the offering and will not receive any of the proceeds from the sale of common stock by the selling stockholders.

Barclays, J.P. Morgan, Morgan Stanley, BofA Securities and Deutsche Bank Securities are serving as active bookrunners for this offering. This offering is being made only by means of a prospectus supplement and related prospectus, copies of which may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 888-603-5847, email: barclaysprospectus@broadridge.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 888-803-9204, email: prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at prospectus@morganstanley.com; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com; or Deutsche Bank Securities, Inc., 60 Wall Street, New York, NY 10005, Attention: Prospectus Department, telephone: 800-503-4611 or by email at: prospectus.cdpg@db.com.

This offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on May 25, 2021. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.

Forward Looking Statements
Certain of the statements made in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the size and terms of the proposed secondary offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that R1 RCM will be able to complete the offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements as predictions of future events, which statements apply only as of the date of this press release. Additional risks and uncertainties relating to the offering, R1 RCM and its business can be found under the heading “Risk Factors” in R1 RCM’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission. Forward-looking statements represent R1 RCM’s beliefs and assumptions only as of the date of this press release. R1 RCM expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as may be required under applicable law.

Contacts:
R1 RCM

Investor Relations  
Atif Rahim  
312.324.5476  
investorrelations@r1rcm.com
  
Media Relations  
Natalie Bennett  
678.585.1206  
media@r1rcm.com


Primary Logo


© GlobeNewswire 2021
All news about R1 RCM INC.
06/02R1 RCM  : Baird Starts R1 RCM at Outperform With $30 Price Target
MT
06/01R1 RCM  : Information relating to Part II, Item 14. “Other Expenses of Iss..
PU
06/01R1 RCM INC.  : Entry into a Material Definitive Agreement, Unregistered Sale of ..
AQ
05/27R1 RCM  : Prices Secondary Offering at $22.50/Share
MT
05/26R1 RCM Announces Pricing of Secondary Offering of 15,000,000 Shares by Sellin..
GL
05/26SECTOR UPDATE : Health Care Stocks Slipping Ahead of Close
MT
05/26R1 RCM  : Stock Declines as CEO Flanagan, Another Stakeholder Begin to Divest Sh..
MT
05/26SECTOR UPDATE : Health Care Stocks Drifting Lower Again
MT
05/25R1 RCM  : Announces Secondary Offering of 15 Million Shares
MT
05/25R1 RCM Announces Commencement of Secondary Offering by Selling Stockholders
GL
More news
Financials (USD)
Sales 2021 1 449 M - -
Net income 2021 94,1 M - -
Net Debt 2021 442 M - -
P/E ratio 2021 -15,0x
Yield 2021 -
Capitalization 6 156 M 6 156 M -
EV / Sales 2021 4,55x
EV / Sales 2022 3,90x
Nbr of Employees 19 600
Free-Float 45,5%
Chart R1 RCM INC.
Duration : Period :
R1 RCM Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends R1 RCM INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 34,29 $
Last Close Price 22,27 $
Spread / Highest target 66,1%
Spread / Average Target 54,0%
Spread / Lowest Target 34,7%
EPS Revisions
Managers and Directors
NameTitle
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Rachel Wilson Chief Financial Officer, Treasurer & Executive VP
Julia Davis Chief Information Officer & Executive VP
John Sparby COO, Executive VP-Operations & Delivery
Corey Perman Executive Vice President-Compliance & Risk
Sector and Competitors
1st jan.Capitalization (M$)
R1 RCM INC.-7.29%6 156
CVS HEALTH CORPORATION20.64%110 618
HCA HEALTHCARE, INC.26.53%68 806
LABORATORY CORPORATION OF AMERICA HOLDINGS30.35%25 907
REDE D'OR SÃO LUIZ S.A.-1.99%25 776
FRESENIUS MEDICAL CARE AG & CO. KGAA1.79%24 222